You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



Pegylated Interferons and Advances in Therapy for Chronic Hepatitis C

  • Authors: Author: Norbert Bräu MD, FACP
Start Activity

Target Audience and Goal Statement

This activity is intended for pharmacists, primary care physicians, and other healthcare professionals involved in the care of patients with hepatitis C.

The goal of this activity is to provide a comprehensive overview of the state of the field regarding hepatitis C, with specific emphasis on current options in therapy and recommended dosing strategies.

Upon completion of this activity, participants should be able to:

  1. Discuss the pathophysiology, natural history, and clinical presentation of hepatitis C.
  2. Assess the currently available options in therapy as they relate to managing the patient with hepatitis C and its complications.
  3. Analyze clinical data supporting recommended dosing strategies for achieving optimal responses to therapeutic protocols in patients with hepatitis C.


  • Norbert Bräu, MD, FACP

    Assistant Professor, Department of Medicine, Division of Infectious Diseases, Mount Sinai School of Medicine, New York, NY; Director, Viral Hepatitis Clinic, Bronx VA Medical Center, Bronx, New York


    Disclosure: Norbert Bräu, MD, FACP, has disclosed that he has received grants for clinical research from Roche, Schering-Plough, and Ortho-Biotech. He has served as an advisor or consultant for Roche and Ortho-Biotech. He has received grants for educational activities from Roche. He has also disclosed that he will be discussing the investigational product peginterferon alfa-2a (Pegasys) and will be discussing the unlabeled uses of epoetin alfa (Procrit).

Accreditation Statements

    For Physicians

  • Medical Education Collaborative, a nonprofit education organization, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medical Education Collaborative designates this educational activity for a maximum of 1 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
    This CME activity is cosponsored by Medical Education Collaborative and Medscape, also an ACCME-accredited provider.

    Contact This Provider

    For Pharmacists

  • Medical Education Collaborative, Inc. has assigned 1 contact hour (0.10 CEUs) of continuing pharmaceutical education credit. ACPE provider number: 815-999-02-203-H04. Certificate is defined as a record of participation.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

The credit that you receive is based on your user profile.


Pegylated Interferons and Advances in Therapy for Chronic Hepatitis C



  1. Prince AM, Brotman B, Grady GF, et al. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet. 1974;2:241-246.
  2. Berman M, Alter HJ, Ishak KG, Purcell RH, Jones EA. The chronic sequelae of non-A, non-B hepatitis. Ann Intern Med. 1979;91:1-6.
  3. Tabor E, Gerety RJ, Drucker JA, et al. Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet. 1978;1:463-466.
  4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-362.
  5. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989;244:362-364.
  6. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989;321:1494-1500.
  7. Colombo M, Kuo G, Choo QL, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. 1989;2:1006-1008.
  8. Kew MC, Houghton M, Choo QL, Kuo G. Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet. 1990;335:873-874.
  9. Choo QL, Weiner AJ, Overby LR, Kuo G, Houghton M, Bradley DW. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull. 1990;46:423-441.
  10. Miyamura T, Saito I, Katayama T, et al. Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis. Proc Natl Acad Sci U S A. 1990;87:983-987.
  11. Brau N, Bini EJ, Shahidi A, et al. Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol. 2002;97:2071-2078.
  12. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
  13. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513-1520.
  14. Bedossa P, Poynard T, The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24:289-293.
  15. Poynard T, Bedossa P, Opolon P, The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997;349:825-832.
  16. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996;334:1691-1696.
  17. Persico M, Persico E, Suozzo R, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology. 2000;118:760-764.
  18. Gholson CF, Morgan K, Catinis G, et al. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am J Gastroenterol. 1997;92:1788-1792.
  19. Puoti C, Magrini A, Stati T, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology. 1997;26:1393-1398.
  20. National Institutes of Health. NIH Consensus Development Conference Statement: Management of Hepatitis C 2002, June 10-12, 2002. Bethesda, Md: NIH Consensus Development Program; 2002:19(1).
  21. Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis. 1997;1:559-568.
  22. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore--an analysis of 309 sex partnerships. J Infect Dis. 1995;171:768-775.
  23. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med. 1991;115:764-768.
  24. Filippini P, Coppola N, Scolastico C, et al. Does HIV infection favor the sexual transmission of hepatitis C? Sex Transm Dis. 2001;28:725-729.
  25. Pineda JA, Rivero A, Rey C, et al. Association between hepatitis C virus seroreactivity and HIV infection in non-intravenous drug abusing prostitutes. Eur J Clin Microbiol Infect Dis. 1995;14:460-464.
  26. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR-19):1-39.
  27. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
  28. Poynard T, Cacoub P, Ratziu V, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat. 2002;9:295-303.
  29. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23:1334-1340.
  30. Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology. 1998;27:914-919.
  31. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology. 1998;27:1730-1735.
  32. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology. 1998;27:1717-1722.
  33. Bierhoff E, Fischer HP, Willsch E, Rockstroh J, et al. Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection. Virchows Arch. 1997;430:271-277.
  34. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26:1-5.
  35. Garcia-Samaniego J, Soriano V, Castilla J, et al, The Hepatitis/HIV Spanish Study Group. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. Am J Gastroenterol. 1997;92:1130-1134.
  36. Darby SC, Ewart DW, Giangrande PL, et al, UK Haemophilia Centre Directors' Organisation. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet. 1997;350:1425-1431.
  37. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463-472.
  38. Brenard R, Horsmans Y, Geubel A. Chronic viral hepatitis and interferons: preliminary results in 60 patients with chronic hepatitis C and cellular mechanism of action. Acta Gastroenterol Belg. 1994;57:230-235.
  39. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35:1002-1009.
  40. Camma C, Di Marco V, Lo Iacono O, et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol. 1998;28:531-537.
  41. Shindo M, Ken A, Okuno T. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer. 1999;85:1943-1950.
  42. McHutchison JG, Davis GL, Esteban-Mur R, et al. Durability of sustained viral response in patients with chronic hepatitis C after treatment with interferon alfa-2b alone or in combination with ribavirin. Hepatology. 2001;34:244A. Abstract 281.
  43. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology. 1998;28:1121-1127.
  44. Larghi A, Tagger A, Crosignani A, et al. Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon- alpha therapy. J Med Virol. 1998;55:7-11.
  45. Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol. 1999;30:783-787.
  46. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303-1313.
  47. Alri L, Duffaut M, Selves J, et al. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. J Hepatol. 2001;35:272-278.
  48. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517-524.
  49. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer. 1998;83:901-909.
  50. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051-1055.
  51. Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001;357:196-197.
  52. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med. 1986;315:1575-1578.
  53. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506-1510.
  54. Lee WM. Therapy of hepatitis C: interferon alfa-2a trials. Hepatology. 1997;26(3 Suppl 1):89S-95S.
  55. Tong MJ, Reddy KR, Lee WM, et al, Consensus Interferon Study Group. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Hepatology. 1997;26:747-754.
  56. Poynard T, Bedossa P, Chevallier M, et al, Multicenter Study Group. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med. 1995;332:1457-1462.
  57. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol. 1996;25:591-598.
  58. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double- blind, placebo-controlled trial. Ann Intern Med. 1995;123:897-903.
  59. McHutchison JG, Gordon SC, Schiff ER, et al, Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [see comments]. N Engl J Med. 1998;339:1485-1492.
  60. Poynard T, Marcellin P, Lee SS, et al, International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-1432.
  61. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis. 1999;19(suppl 1):57-65.
  62. PEG-Intron® package insert. Kenilworth, NJ: Schering Corporation; 2000.
  63. Pharmacokinetic characteristics of 40 kD Peginterferon alfa-2a. Roche. Data on file. 2002.
  64. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.
  65. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673-1680.
  66. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395-403.
  67. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
  68. Fried MW, Shiffman M, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
  69. Rebetol® package insert. Kenilworth, NJ: Schering Corporation; 2001.
  70. Hadziyannis SJ, Cheinquer H, Morgan TR, et al. Peginterferon alfa-2a (40kd) in combination with ribavirin: efficacy and safety results from a phase 3, randomized, double blind, multicenter study examining the effect of duration of treatment, and the RBV dose. Program and abstracts of the 37th Annual Meeting of the European Association for the Study of the Liver; April 18-21, 2002; Madrid, Spain. Abstract 536.
  71. Van Thiel DH, Faruki H, Friedlander L, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology. 1995;42:907-912.
  72. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther. 2002;16:1091-1099.
  73. Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002;63:194-198.
  74. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly recombinant human erythropoietin (epoetin alfa) facilitates optimal ribavirin (RBV) dosing in hepatitis C virus (HCV)-infected patients receiving interferon-a-2b (IFN)/RBV combination therapy. Gastroenterology. 2001;120:A64. Abstract 340.
  75. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001;34:188-193.
  76. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
  77. Soriano V, Garcia-Samaniego J, Bravo R, et al, Hepatitis-HIV Spanish Study Group. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis. 1996;23:585-591.
  78. Landau A, Batisse D, Piketty C, et al. Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS. 2001;15:2149-2155.
  79. Sauleda S, Juarez A, Esteban JI, et al. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology. 2001;34:1035-1040.
  80. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002;8:350-355.
  81. Davis GL, Esteban-Mur R, Rustgi V, et al, International Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1998;339:1493-1499.
  82. Cummings KJ, Lee SM, West ES, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta- analysis of randomized trials. JAMA. 2001;285:193-199.
  83. Saracco G, Ciancio A, Olivero A, et al. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology. 2001;34:133-138.
  84. Hepatitis C Antiviral Long-term Treatment against Cirrhosis [HALT-C] trial. Available at: Accessed September 20, 2002.
  85. National AIDS Treatment Advocacy Project. Hepatitis C maintenance therapy studies. Available at: Accessed September 20, 2002.
  86. NIH trial 98-DK-0003. Available at: Accessed on September 20, 2002.